Announcement of the company's cash capital increase and base date

Board of directors of the company waived subscription rights exceeding half of the total subscribable shares. Shares to be subscribed by designated persons

Letter received from National Medical Products Administration (NMPA) of China regarding Adagloxad Simolenin (OBI-822) Phase III clinical study to be resubmitted after supplementation

Supplementary announcement for the company to issue ordinary shares through rights offering

Supplementary announcement for 2019 Annual General Meeting

Announcement for the company to issue ordinary shares through rights offering and bank designated for collection and deposition

Clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical study by Ministry of Health of the Russian Federation

Announcement for the company to issue ordinary shares through rights offering

Announcement of capital change registration for the treasury share retirement

The board of directors have resolved not to distribute dividends for 2018